Five-year cardiovascular outcomes in patients with chronic myeloid leukemia treated with imatinib, dasatinib or nilotinib: data from a large multinational collaborative network

Abstract Background BCR-ABL tyrosine kinase inhibitors (TKI) have revolutionized the treatment of patients with chronic myeloid leukemia (CML). However, concern has arisen about cardiac safety profile these drugs. Purpose To compare long-term risks adverse cardiovascular and cerebrovascular events (ACE), heart failure or left ventricular ejection fraction (LVEF) <50% venous thromboembolic (VTE) in CML treated first-line Bcr-ABL TKIs, using data from a large multinational network. Methods Patients aged ≥18 years imatinib dasatinib nilotinib without prior disease. We used propensity score matching to balance cohorts. The 5-year cumulative incidences hazard ratios were calculated. Results identified 3,722 under Imatinib (n=1,906), Dasatinib (n=1,269) Nilotinib (n=547). compared showed higher risk for ACE (hazard ratio 2,13, 95% IC 1.15–3.94, p=0.016). presented lower than 0.50, 0.30–0.83, p=0.0074). In relation LVEF <50%, had 9.41, 1.22–72.17, p=0.03), but no significant difference was observed between 0.48, 0,215–1.01, p=0.064). probability survival (Kaplan Meier curves) ACE, VTE are depicted Central Illustration. Conclusions cohort CML, those events, while imatinib. dasatinib, not when nilotinib. Funding Acknowledgement Type funding sources: None.